Passer au contenu principal

Denis Claude Roy

Roy, Denis Claude

Scientific Director

Affiliation

Université de Montréal

Research Axes

Immunology-oncology

Contact information

Phone: 514-252-3400, poste3331

denis-claude.roy@umontreal.ca

Team

  • Jean-Philippe Bastien
  • Hassan Damen
  • Vibhuti Dave
  • Nasser Masroori
  • Cédric Mathieu
  • Annabelle Minguy
  • Alexandre Passedat
  • Jaime Sanchez-Dardon
  • Christian Tebid
  • Jessica Trottier
  • Nabil Zeidan

Dr. Denis Claude Roy is a hematologist and full professor in the Faculty of Medicine at Université de Montréal.  He is the director of the Cellular Therapy Research Unit, the scientific and medical director of the Centre of Excellence for Cellular Therapy, the scientific director of the Centre de recherche de l'Hôpital Maisonneuve-Rosemont and the director of research at the CIUSSS de l'Est-de-l’Île-de-Montréal. Recognized for his expertise in stem cell research, Dr. Roy is the executive director of CellCAN, the Canadian network of regenerative medicine and cellular therapy for knowledge mobilization, and the scientific director of the Centre for Commercialization of Cancer Immunotherapy (C3i).

His research interests lie in the immunobiology of stem cell transplantation, with a particular focus on the treatment of stem cell grafts to eliminate the risk of graft rejection and optimize their anti-cancer activity.

Research Unit

Cellular Therapy

    Research themes

    • Immunology of leukemias and lymphomas: translational research.
    • Autologous and allogeneic hematopoietic stem cell transplantation.
    • Treatment of hematopoietic cell grafts: selective elimination of alloreactive T lymphocytes to prevent and treat graft-versus-host disease.
    • Specific targeting of malignant cells using photodynamic and immunological therapies; study of the mechanisms of action and optimization of monoclonal antibodies and immunoconjugates.
    • Growth factors and expansion of hematopoietic stem cells and blood progenitors.

    Research

    Our research goal is to use cellular and immunological approaches to fight hematological cancers such as leukemia and lymphoma.  Our team therefore studies different monoclonal antibodies and immunoconjugates as well as a photodynamic approach to destroy cancer cells and alloreactive cells.

    We have developed particular expertise in translational research to transfer fundamental discoveries to patients. Through this research, we have identified new hematological and immunological strategies and applied them in early clinical studies (Phase 1 and 2). Our unit serves as the principal investigator for two multicentre studies (Canada and United States) to evaluate a new photodynamic therapy.

    We are also working on the expansion of hematopoietic stem cells and blood cell progenitors to enable and accelerate hematological and immunological reconstitution post-transplantation.

      • Roy, DC, Lachance, S., Cohen, S., Delisle, JS, Kiss, T., Sauvageau, G., Busque, L., Ahmad, I,, Bernard, L., Bambace, N., Sidi Boumédine, R., Guertin, MC, Rezvani, K,, Mielke, S., Perreault, C., Roy, J., Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis, British Journal of Haematology 2019 May 28. PubMed PMID: 31135970.
        More detail
      • Zeidan N, Damen H, Roy DC*, Dave VP* (*co-auteurs seniors), Critical Role for TCR Signal Strength and MHC Specificity in ThPOK-Induced CD4 Helper Lineage Choice, J Immunol. 2019 Apr 29.
        More detail
      • Ciurea, S.O., Al Malki, M.M., Kongtim, P., Fuchs, E.J., Luznik, L., Huang, X.J., Ciceri, F., Locatelli, F., Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Ben Soussan, P., Arnault, Y., Handgretinger, R., Roy, D.C., O'Donnell, P.V., Bashey, A., Solomon, S., Romee, R., Gayoso, J., Lazarus, H.M., Ballen, K., Savani, B.N., Mohty, M, Nagler, A., The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2019, Mar 4.
        More detail
      • Ciurea, S.O., Cao, K., Fernandez-Vina, M., Kongtim, P., Malki, M.A., Fuchs, E., Luznik, L., Huang, X.J., Ciceri, F., Locatelli, F., Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Handgretinger, R., Roy, D.C., O'Donnell, P., Bashey, A., Lazarus, H.M., Ballen, K., Savani, B.N., Mohty, M., Nagler, A., The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation., Bone Marrow Transplant. 2018 May;53(5):521-534.
        More detail
      • Del'Guidice, T., Lepetit-Stoffaes, J.P., Bordeleau, L.J., Roberge, J., Théberge, V., Lauvaux, C., Barbeau, X., Trottier, J., Dave, V., Roy, D.C., Gaillet, B., Garnier, A., Guay, D., Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells. PLoS One. 2018 Apr 4;13(4).
        More detail
      • Roy D.C., Perreault C., Major vs minor histocompatibility antigens. Blood. 2017 Fevrier 9;129(6):664-666.
        More detail
      • Noiseux, N., Mansour, S., Weisel, R., Stevens, L.M., Der Sarkissian, S., Tsang, K., Crean, A.M., Larose, E., Li, S.H., Wintersperger, B., Vu, M.Q., Prieto, I., Li, R.K., Roy, D.C., Yau, T.M.. The IMPACT CABG trial: multicenter, randomized clinical trial of CD133+ stem cell therapy during coronary artery bypass grafting for ischemic cardio–myopathy. J Thorac Cardiovasc Surg. 2016 Dec;152(6):1582-1588.e2.
        More detail
      • Granados, D., Rodenbrock, A., Laverdure, JP, Côté, C., Caron-Lizotte, O., Carli, C., Pearson, H., Janelle, V., Durette, C., Bonneil, E., Roy, DC, Delisle, JS, Lemieux, S., Thibault, P., Perreault, C., Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers. Leukemia. 2016 Feb;30 :1344-54.
        More detail
      • Roy, D.C., Alarco, A.M., Isasi, R., CellCAN : A unique enabler of Regenerative Medicine and Cell Therapy in Canada. Stem Cells and Development 2014 Dec; 23 Suppl 1:24-8.
        More detail
      • Fares, I., Chagraoui, J., Gareau, Y., Gingras, S., Ruel, R., Mayotte, N., Csaszar, E., Knapp, D., Miller, P., Ngom, M., Imren, S., Roy, D.C., Watts, K.L., Kiem, H.P., Herrington, R., Iscove, N.N., Humphries, R.K., Eaves, C.J., Cohen, S., Marinier, A., Zandstra, P.W., Sauvageau, G., Pyrimido-Indole Derivatives Are Novel Agonists of Human Cord Blood Hematopoietic Stem Cell Science. Self-renewal. Science 2014 Sep 19;345(6203):1509-12. doi: 10.1126/PMID.1256337.
        More detail

      Education

      • Postdoctoral fellowship, tumour immunology

        Harvard University

      • FRCPC, Hematology

        Université de Montréal

      • Doctor of Medicine

        Université de Montréal